Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
08 sept. 2021 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral...
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
07 sept. 2021 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral...
Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
17 août 2021 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Announces Pricing of Initial Public Offering
26 juil. 2021 21h05 HE
|
Candel Therapeutics
NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Completes $28.7 Million Series B Financing
04 janv. 2019 14h33 HE
|
Candel Therapeutics
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other...
Advantagene Announces Clinical Trial Collaboration
27 avr. 2018 07h00 HE
|
Advantagene, Inc.
AUBURNDALE, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Advantagene, Inc. today announced that the company entered into a clinical trial collaboration with Bristol-Myers Squibb (NYSE:BMY) to evaluate...